The impact of plasma ionized magnesium levels before magnesium supplementation on glycemic control in patients with type 2 diabetes mellitus

Impact of plasma ionized magnesium levels on glycemic control in patients with type 2 diabetes mellitus: Experimental study

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250117005

Enrollment

Registered

2025-01-17

Start date

2025-03-03

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes mellitus Type 2 Diabetes mellitus Plasma ionized magnesium level Magnesium supplement

Interventions

Magnesium chloride 20% (elemental magnesium 24 mg/mL) 1 teaspoon, orally 4 times a day for 3 months

Experimental Drug

Magnesium supplement

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Type2 diabetes mellitus 2. HbA1c 7.0-10.0% 3. low or normal plasma ionized magnesium

Exclusion criteria

Exclusion criteria: 1. Disease that affect to drug absorption e.g. malabsorption, short bowel syndrome 2. Chronic kidney disease > stage 3 3. Bleeding disorders e.g. low platelet or prolonged PT/PTT 4. Had recieved magnesium supplementation within 3 month 5. The last 2 times HbA1c level differed more than 20 percent 6. Pregnancy

Design outcomes

Primary

Measure	Time frame
HbA1c levels At 3 months after end of the intervention Capillary electrophoresis for HbA1c	—

Secondary

Measure	Time frame
Fasting plasma glucose and insulin At 3 months after end of the intervention Enzymatic method for glucose; Electrochemiluminescence immunoassay for insulin	—

Countries

Thailand

Contacts

Public ContactSurawadee Chanthanuwat

Faculty of Medicine, Prince of Songkla University

csurawadee@gmail.com0808637667

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026